rVWF: treatment finally reaches the modern age

Blood. 2015 Oct 22;126(17):1975-6. doi: 10.1182/blood-2015-08-664052.

Abstract

In this issue of Blood, Gill et al describe the results of the first phase 3 clinical trial evaluating recombinant von Willebrand factor (rVWF) for the treatment of hemorrhagic events in all patients with von Willebrand disease (VWD).

Publication types

  • Comment

MeSH terms

  • Female
  • Hemostatics*
  • Humans
  • Male
  • Recombinant Proteins / pharmacokinetics*
  • von Willebrand Diseases / drug therapy*
  • von Willebrand Factor / pharmacokinetics*

Substances

  • Hemostatics
  • Recombinant Proteins
  • von Willebrand Factor